TOTakashi Otsuka

Takashi Otsuka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takashi Otsuka has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Fumi Uemura

    First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, 807-8555 Japan

    1 shared publication
  • Hiroko Mori

    First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushyu-shi 807-8555, Japan

    1 shared publication
  • Kei Sugai

    First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan

    1 shared publication
  • Keiichi Torimoto

    First Department of Internal Medicine, School of Medicine University of Occupational and Environmental Health Kitakyushu Japan

    1 shared publication
  • Kenichi Tanaka

    Department of Rheumatology and Diabetes, Wakamatsu Hospital of the University of Occupational and Environmental Health, Kitakyushu 808-0024, Japan

    1 shared publication
  • Maiko Hajime

    First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan

    1 shared publication

Latest Publications

  • Open Access

    Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus

    by Keiichi Torimoto, Yosuke Okada, Hiroko Mori, Takashi Otsuka, Mayuko Kawaguchi, Megumi Matsuda, Fumi Kuno, Kei Sugai, Satomi Sonoda, Maiko Hajime, et al.

    Basic studies have shown that glucagon-like peptide-1 (GLP-1) analogs exert a direct protective effect on the vascular endothelium in addition to their indirect effects on postprandial glucose and lipid metabolism. GLP-1 analogs are also reported to inhibit postprandial vascular endothelial dysfunction. This study examined whether the GLP-1 analog exenatide inhibits postprandial vascular endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM). Seventeen patients with T2DM underwent a meal tolerance test to examine changes in postprandial vascular endothelial function and in glucose and lipid metabolism, both without exenatide (baseline) and after a single subcutaneous injection of 10 μg exenatide. Vascular endothelial function was determined using reactive hyperemia index (RHI) measured by peripheral arterial tonometry before and 120 min after the meal loading test. The primary endpoint was the difference in changes in postprandial vascular endothelial function between the baseline and exenatide tests. The natural logarithmically-scaled RHI (L_RHI) was significantly lower after the baseline meal test but not in the exenatide test. The use of exenatide resulted in a significant decrease in triglycerides (TG) area under the curve and coefficient of variation (CV). The change in L_RHI correlated with changes in CV of triglycerides and HDL-cholesterol. Multivariate analysis identified changes in triglyceride CV as the only determinant of changes in L_RHI, contributing to 41% of the observed change. Exenatide inhibited postprandial vascular endothelial dysfunction after the meal loading test, suggesting that exenatide has a multiphasic anti-atherogenic action involving not only glucose but also lipid metabolism. ClinicalTrials.gov: UMIN000015699 .